Evidence map›Paper›PMID 41250206›Full record

ArticleJournal of nanobiotechnology2025

AMFR-mediated ER-phagy regulation and therapeutic targeting in osteosarcoma: a multifunctional nanoplatform strategy.

Qirui Zhao, Xiaoqing Lu, Tongtong Xu, Zixuan Gao, Linjia Peng, Binyu Zhu, Weicheng Wang, Zhigang Liu, Guangjie Yang, Hui Zhao and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Qirui Zhao *Department of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Xiaoqing Lu *Department of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Tongtong XuGCP lab, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Zixuan GaoMedical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, No. 357 Ximen Street, Kaifeng, 475000, Henan Province, China.
Linjia PengMedical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, No. 357 Ximen Street, Kaifeng, 475000, Henan Province, China.
Binyu ZhuInstitute of Nano Biomedicine and Engineering, School of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai JiaoTong University, No. 800 Dongchuan Road, Shanghai, 200240, China.
Weicheng WangInstitute of Nano Biomedicine and Engineering, School of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai JiaoTong University, No. 800 Dongchuan Road, Shanghai, 200240, China.
Zhigang LiuDepartment of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Guangjie YangDepartment of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Hui ZhaoDepartment of Vascular Surgery, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Zhiming SongDepartment of Cardiology, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Qiankun LouDepartment of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Jiaming LiDepartment of Orthopedics, The First Affiliated Hospital of Henan University, Kaifeng, 475000, China.
Zhiguang RenMedical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, No. 357 Ximen Street, Kaifeng, 475000, Henan Province, China.
Zhe YuMedical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, No. 357 Ximen Street, Kaifeng, 475000, Henan Province, China.
de la Fuente Jesus MInstitute of Nano Biomedicine and Engineering, School of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai JiaoTong University, No. 800 Dongchuan Road, Shanghai, 200240, China.
Daxiang CuiMedical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, No. 357 Ximen Street, Kaifeng, 475000, Henan Province, China. dxcui@sjtu.edu.cn.ORCID http://orcid.org/0000-0003-4513-905X

Funding

Innovation Group Project of National Natural Science Foundation of China 81921002National Key Research and Development Program of China 2017FYA0205301Natural Science Foundation of Shanghai 22ZR1467600Project of International Cooperation and Exchanges of the National Natural Science Foundation of China 82020108017Projects of Shanghai Science and Technology Commission 21DZ2203200, 20142201300
6 · The paper itself

Abstract

This work explores how Autocrine Motility Factor Receptor (AMFR)-driven ubiquitination of Family with Sequence Similarity 134 Member B (FAM134B) in hypoxia adaptation and endoplasmic reticulum-selective autophagy (ER-phagy) in osteosarcoma (OS), aiming to develop a stimuli-responsive nanoplatform (S-SNACs@TPZ@Cas-A) for targeted therapy. Transcriptomic analysis identifies the AMFR-FAM134B axis as crucial for OS survival under hypoxic conditions. The nanoplatform, thoroughly characterized via established methods, co-delivers CRISPR-Cas9 RNP and tirapazamine to disrupt AMFR and enhance reactive oxygen species production, inhibiting tumor growth in mouse models. In vitro assays confirm decreased FAM134B ubiquitination and ER-phagy inhibition. In vivo, S-SNACs@TPZ@Cas-A reduces tumor volume, metastasis, and enhances immune response without significant toxicity. Second near-infrared window imaging validates targeted drug delivery. This approach provides a precise strategy to disrupt hypoxia tolerance in OS and potentially other hypoxia-tolerant tumors, offering promise for improved therapeutic outcomes.

Indexed as

AutophagyBone NeoplasmsEndoplasmic ReticulumNanoparticlesOsteosarcomaAnimalsCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudeReactive Oxygen SpeciesTirapazamineUbiquitinationReactive Oxygen SpeciesTirapazamineAMFR-FAM134B axisCRISPR-Cas9 nanoplatformEndoplasmic reticulum autophagyHypoxia adaptationOsteosarcomaTheranostic

Identifiers

PMID41250206
PMCPMC12625341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.